« Previous
Next »
Contraception
Volume 64, Issue 4
, Pages 217-222
, October 2001
Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations
References
- Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
- Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
- . Plasma resistance to activated protein C (an important link between venous thromboembolism, and combined oral contraceptives, a short review). Eur J Contracept Reprod Health Care. 1996;1:3–11
- . Activated protein C resistance—a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem. 1997;35(Suppl 7):501–516
- . Factor V Leiden (should all women be screened prior to commencing the contraceptive pill?). Blood Rev. 1999;13(Suppl 1):8–13
-
Development of resistance to activated protein C during pregnancy.
Int J Hematol. 1995;90:725–727
-
.
Resistance to activated protein C is reduced in women using oral contraceptives.
Blood Coagul Fibrinol. 1994;5:853–854
-
Resistance to activated protein C in healthy women taking oral contraceptives.
Brit J Hematol. 1995;9:465–470
-
Acquired APC-resistance and oral contraceptives (differences between two functional tests).
Brit J Hematol. 1999;105:88–94
- ProC Global (the first functional screening assay for the complete protein C pathway). Clin Chem. 1997;43:1719–1723
-
.
The PCAT—a simple screening assay for assessing the functionality of the protein C anticoagulant pathway.
Thrombosis Res. 1995;79:217–222
-
.
Thrombophilic mechanisms of OCs.
Int J Fertil Women S Med. 1997;42(Suppl 1):170–176
- . Homozygous patients with APC-resistance may remain paucisymptomatic or asymptomatic during oral contraception. Blood Coagul Fibrinolysis. 1996;7:590–594
- . Resistance to activated protein C in women using oral contraceptives. Semin Thromb Hemost. 1998;24(Suppl 5):423–430
- . Activated protein C resistance, and deficiencies of antithrombin III, protein C or protein S, and the risk of thromboembolic disease in users of oral contraceptives. Eur J Contracept Reprod Health Care. 1998;3(Suppl 2):65–74
- . Blood coagulation, and oral contraceptives. Contraception. 1998;57:203–209
-
Screening for activated protein C resistance before oral contraceptive treatment (a pilot study).
Contraception. 1999;59:292–299
PII: S0010-7824(01)00253-0
© 2001 Elsevier Science Inc. All rights reserved.
« Previous
Next »
Contraception
Volume 64, Issue 4
, Pages 217-222
, October 2001
